Verofylline, a methylxanthine bronchodilator, in asthma.

Abstract

Verofylline, a long-acting polysubstituted methylxanthine bronchodilator, was taken orally by eight adult patients with asthma in a double-blind, crossover tolerance study. Peak expiratory flow, forced vital capacity, and its subdivisions were measured weekly 2, 4, and 6 hr after oral dosing with drug or placebo. Peak drug activity developed between 4 and 6 hr after dosing. Subject tolerance was good at the doses used. Dose-response curves for mean forced expiratory volume in one second, peak expiratory flow rate, and forced expiratory flow at the end of 4 hr were greater after 0.05 mg/kg verofylline than after placebo or higher doses of verofylline. Mean percent change in forced vital capacity remained increased as long as 6 hr after 0.15 mg/kg active drug. Verofylline was not very effective as a bronchodilator at the doses used.

• Authors: R C Young Jr, S G Lucas, E A Morris, J Pittman, R E Rachal, F J Malveaux, W M Booker
• Journal: Clinical pharmacology and therapeutics (Clin Pharmacol Ther) Vol. 36 Issue 6 Pg. 811-6 (Dec 1984) ISSN: 0009-9236 [Print] United States
• PMID: 6388955 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bronchodilator Agents
• verofylline
• Theophylline

Topics

• Administration, Oral
• Adult
• Asthma (drug therapy)
• Bronchi (drug effects)
• Bronchodilator Agents (pharmacology, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Evaluation
• Female
• Humans
• Male
• Maximal Expiratory Flow Rate
• Maximal Midexpiratory Flow Rate
• Middle Aged
• Peak Expiratory Flow Rate
• Spirometry
• Theophylline (analogs & derivatives, therapeutic use)
• Vital Capacity